SyntheX Overview

  • Founded

  • 2016

Founded
  • Status

  • Private

  • Employees

  • 21

Employees
  • Latest Deal Type

  • Early Stage VC

  • (Cancelled)
  • Investors

  • 11

SyntheX General Information

Description

Developer of drug discovery platforms using synthetic biology designed to modulate proteins. The company's platform uses genetically engineered circuits, technologies and proprietary DNA encoded peptide and macrocycle libraries that rely on intracellular drug selection as opposed to in vitro screening, enabling healthcare institutions to better serve human health for the treatment of cancer and rare diseases.

Contact Information

Website
www.synthexlabs.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 409 Illinois Street
  • San Francisco, CA 94158
  • United States
+1 (415) 000-0000

SyntheX Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SyntheX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Early Stage VC Cancelled Pre-Clinical Trials
7. Early Stage VC 03-Sep-2020 000 000.00 Completed Pre-Clinical Trials
6. Debt - PPP 27-Apr-2020 00.00 Completed Pre-Clinical Trials
5. Accelerator/Incubator 03-Jul-2018 00.00 Completed Pre-Clinical Trials
4. Seed Round 27-Apr-2017 00.000 00.00 000.00 Completed Pre-Clinical Trials
3. Accelerator/Incubator 27-Apr-2017 00000 Completed Pre-Clinical Trials
2. Accelerator/Incubator 01-Mar-2016 $250K $250K Completed Product In Beta Test
1. Accelerator/Incubator 01-Jan-2016 Completed Product In Beta Test
To view SyntheX’s complete valuation and funding history, request access »

SyntheX Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Seed 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view SyntheX’s complete cap table history, request access »

SyntheX Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of drug discovery platforms using synthetic biology designed to modulate proteins. The company's platform uses
Biotechnology
San Francisco, CA
21 As of 2022
000.00
00000 00000

000000

rure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteu
0000000000000
Watertown, MA
000 As of 0000
00000
000000000 00000

000000

ommodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fu
0000 000000000
South San Francisco, CA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

SyntheX Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kymera Therapeutics Formerly VC-backed Watertown, MA 000 00000 000000000 00000
000000 000000 Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 00000000
0000000 Venture Capital-Backed San Diego, CA 00 0000 00000000000 0000
0000000 Formerly VC-backed New Haven, CT 000 00000 000000000 00000
You’re viewing 5 of 13 competitors. Get the full list »

SyntheX Patents

  • 19

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 2

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

SyntheX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220298503-A1 Selective degradation of proteins Pending 15-May-2019 00000000000
GB-202008948-D0 Peptides for inhibiting rad51 Active 22-Nov-2017 000000000
GB-2584210-A Peptides for inhibiting rad51 Active 22-Nov-2017 000000000 0
US-20200361991-A1 Compounds for selective disruption of protein-protein interactions Pending 22-Nov-2017 000000000
GB-2584210-B Peptides for inhibiting rad51 Active 22-Nov-2017 C07K19/00 0
To view SyntheX’s complete patent history, request access »

SyntheX Executive Team (3)

Name Title Board Seat Contact Info
Maria Soloveychik Ph.D Co-Founder, Chief Executive Officer & Board Member
Charly Chahwan Co-Founder, Chief Scientific Officer & Board Member
Tri Luong Head of Finance & Operations
To view SyntheX’s complete executive team members history, request access »

SyntheX Board Members (3)

Name Representing Role Since
Arvind Gupta SOSV Board Member 000 0000
Charly Chahwan SyntheX Co-Founder, Chief Scientific Officer & Board Member 000 0000
Maria Soloveychik Ph.D SyntheX Co-Founder, Chief Executive Officer & Board Member 000 0000
To view SyntheX’s complete board members history, request access »

SyntheX Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SyntheX Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
OMX Ventures Venture Capital Minority 000 0000 000000 0
MBC BioLabs Accelerator/Incubator 000 0000 000000 0
8VC Venture Capital Minority 000 0000 000000 0
Augustin Ku Angel (individual) Minority 000 0000 000000 0
Jason Camm Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial